This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.
The closely watched XBI biotech index has fallen more than 10%…
This story from statnews.com was posted on 2023-09-25 by @petalfl.